Company performance
Add to research
Current Price
as of Jun 11, 2025$1.57
P/E Ratio
N/A
Market Cap
$3.31M
Description
Add to research
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or "uncontrollable itching" in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.
Metrics
Add to research
Overview
- HQBridgewater, NJ
- SectorHealth Technology
- IndustryBiotechnology
- TickerHILS
- Price$1.57-1.26%
Trading Information
- Market cap$3.31M
- Float98.34%
- Average Daily Volume (1m)28,695
- Average Daily Volume (3m)125,625
- EPS-$7.79
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$2.54M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$2.55M
- EV$2.94M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/BN/A
- Debt/EquityN/A
Documents
Add to research
SEC Filings
Factset Street Account